Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Inclusion Criteria: * Able to daily self-administer AMG 337 orally as a whole capsule * Male or female 18 years of age or over. * Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid tumor (Cohort 2) for which subject has received prior therapy for advanced disease, for which no standard therapy exists, or subject refuses standard therapy * Tumor MET amplified by protocol-specified centralized testing. * Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1 * (ECOG) Performance Status of 0, 1 or 2 Exclusion Criteria: * Known central nervous system metastases * Candidate for curative surgery or definitive chemoradiation * Peripheral edema \> grade 1 * Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption * Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the opinion of the investigator or Amgen physician, if consulted, would not pose a risk to subject safety * Detectable Hepatitis C virus (indicative of active Hepatitis C) * Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment * Prior treatment with small molecule inhibitors of the MET pathway. Other protocol defined inclusion criteria may apply.